Changchun GeneScience Pharmaceutical (GenSci), a subsidiary of Changchun High-Tech Industries (Group), hosted a groundbreaking ceremony for its new global headquarters and research & development (R&D) center at Shanghai Zhangjiang International Medical Park on December 15th. This facility is on track to be fully operational by 2027, with a capacity to accommodate 2,000 R&D professionals.

"GenSci has built a globally innovative and competitive R&D product pipeline," Dr. Jin Lei, Chief Scientist and General Manager of GenSci declared. "By 2025, the firm will boast an extensive portfolio, with the expectation of launching more than four top-tier innovative drugs and five novel medical devices annually in the years to come."

The establishment of the R&D center sets the stage for GenSci to further advance the convergence of industry, academia, research and the medical community. Leveraging state-of-the-art R&D capabilities and the application of artificial intelligence technologies, GenSci is well-positioned to provide premium health solutions for women and children. The initiative aligns with GenSci's commitment to harnessing science and technology to protect and enhance the health of these vulnerable groups.

Since its founding in 1997, GenSci has introduced several groundbreaking therapies, including the GenSci Recombinant Human Growth Hormone, GenSci Heng Recombinant Human Follicle-Stimulating Hormone and Jinfuning Recombinant Human Granulocyte-Stimulating Factor Gel.